Please login to the form below

MK-3475

This page shows the latest MK-3475 news and features for those working in and with pharma, biotech and healthcare.

GSK wins approval for skin cancer drug Mekinist in EU

be taken up by immune checkpoint inhibitors - BMS' nivolumab and Merck &Co's pembrolizumab (MK-3475) - which are currently in late-stage testing.

Latest news

Merck could win anti-PD1 therapy race in Europe

Pembrolizumab (formerly lambrolizumab; MK-3475) is one of the highlights of Merck's R&D pipeline and is being evaluated across more than 30 types of cancer, with peak sales estimated
ASCO: Merck’s anti-PD1 impresses in skin and lung cancer

ASCO: Merck’ s anti-PD1 impresses in skin and lung cancer. Promising MK-3475 immunotherapy to be known as pembrolizumab. ... New data on Merck &Co's recently-filed anti-PD1 drug pembrolizumab (MK-3475) suggest the drug could be a 'paradigm shift' in
AZ starts pivotal trials of lung cancer immunotherapy

Meanwhile, Merck &Co's MK-3475 - filed for melanoma earlier this year - and Bristol-Myers Squibb's nivolumab for NSCLC are targeting a related receptor called PD1.
FDA grants priority review to Merck’s cancer antibody

FDA grants priority review to Merck’ s cancer antibody. Will speed up assessment of MK-3475 in skin cancer melanoma. ... Merck has also signed agreements with rivals Pfizer, Amgen and Incyte to test MK-3475 in combination with other oncology drugs
Novartis enters PD-1 race via CoStim acquisition

Of these Merck appears to be in the lead, as it has filed a rolling marketing submission for its MK-3475. ... therapies seems backed up by Merck's recent announcement of a series of collaborations on MK-3475 with other drugmakers.

More from news
Approximately 7 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Interview: Bruno Strigini, MSD

Here among the products he points to are the company's anti-PD-1 immunotherapy MK-3475, for which a rolling approval was filed earlier this year as a second-line
Pharma deals during February 2014

Merck &Co also signed three separate agreements with Amgen, Incyte and Pfizer to investigate combination regimes with its experimental anti-PD-1 immunotherapy, MK-3475 (see Box 1). ... MK-3475 was awarded FDA breakthrough therapy status for advanced

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Bruno Strigini leaves Merck & Co for Novartis

Leading the field though is Strigini's former company Merck &Co, which has already filed MK-3475 in the US to treat advanced melanoma.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Account Manager – Healthcare Advertising: Salary TBC

Account Director or Senior Account Director: Salary TBC

Senior Writer, Healthcare Advertising, London: Excellent package

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Market Access Consultant - Greater Manchester: Negotiable

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Medical Writer - Creative and Scientific Projects: DOE

Systematic Review Lead- London: Negotiable

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Associate Scientific Director: Salary TBC

Sudler London - Account Director: Competitive

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Healthcare PR Director: £100, 000 – £120, 000 benefits

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Graduate Scientific Editor: DOE

Subscribe to our email news alerts

PMHub

Add my company

Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....